Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected

被引：0

作者：

Gallant, Joel ^{[1
]}

Brunetta, Jason ^{[2
]}

Crofoot, Gordon ^{[3
]}

Benson, Paul ^{[4
]}

Mills, Anthony ^{[5
]}

Brinson, Cynthia ^{[6
]}

Oka, Shinichi ^{[7
]}

Cheng, Andrew ^{[8
]}

Garner, Will ^{[8
]}

Fordyce, Marshall ^{[8
]}

Das, Moupali ^{[8
]}

McCallister, Scott ^{[8
]}

机构：

[1] Southwest CARE Ctr, 649 Harkle Rd,Ste E, Santa Fe, NM 87505 USA

[2] Univ Toronto, Family & Community Med, Toronto, ON, Canada

[3] Crofoot Res Ctr, Houston, TX USA

[4] Be Well Med Ctr, Berkley, MI USA

[5] Southern Calif Mens Med Grp, Los Angeles, CA USA

[6] Cent Texas Clin Res, Austin, TX USA

[7] Natl Ctr Global Hlth & Med, AIDS Clin Ctr, Tokyo, Japan

[8] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

来源：

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2016年 / 73卷 / 03期

关键词：

tenofovir alafenamide; TAF; elvitegravir; HIV; HBV; coinfection; bone; renal; TENOFOVIR DISOPROXIL FUMARATE; HIV-INFECTED PATIENTS; CHRONIC HEPATITIS-B; ANTIRETROVIRAL-NAIVE; ABACAVIR-LAMIVUDINE; EMTRICITABINE; PHARMACOKINETICS; EFAVIRENZ; DENSITY;

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has high efficacy and improved renal and bone safety in multiple phase 3 trials; TAF single agent is being studied in 2 phase 3 trials in patients with chronic hepatitis B. We report the results of an open-label, noncomparative switch study evaluating the efficacy and safety of E/C/F/TAF in HIV/hepatitis B virus (HBV)-coinfected adults. At 48 weeks, 91.7% of the 72 participants maintained or achieved virologic suppression (HIV-1 RNA <50 copies/mL; HBV DNA <29 IU/mL). Seroconversion occurred in 2.9% of hepatitis B surface antigen-positive participants and in 3.3% of HBV e antigen-positive participants; 40% of those with abnormal alanine aminotransferase normalized. E/C/F/TAF was associated with improved renal function and reduced bone turnover. These data support the use of E/C/F/TAF in treating HIV/HBV coinfection.

引用

页码：294 / 298

页数：5

共 50 条

[41] Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial
Orkin, Chloe
Molina, Jean-Michel
Negredo, Eugenia
Arribas, Jose R.
Gathe, Joseph
Eron, Joseph J.
Van Landuyt, Erika
Lathouwers, Erkki
Hufkens, Veerle
Petrovic, Romana
Vanveggel, Simon
Opsomer, Magda
LANCET HIV, 2018, 5 (01): : E23 - E34
[42] TENOFOVIR ALAFENAMIDE (TAF) IN A SINGLE TABLET REGIMEN IN INITIAL HIV-1 THERAPY
Pozniak, Anton
Wohl, David
Thompson, Melanie
DeJesus, Edwin
Podzamczer, Daniel
Molina, Jean Michel
Crofoot, Gordon
Callebaut, Christian
Martin, Hal
McCallister, Scott
SEXUALLY TRANSMITTED INFECTIONS, 2015, 91 : A49 - A49
[43] Safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in HIV-infected adults on chronic haemodialysis
Eron, J.
Kalayjian, R.
Wurapa, A.
Stephens, J.
McDonald, C.
Wilkin, A.
McKellar, M.
Custodio, J.
Jiang, S.
SenGupta, D.
Castles, R.
Das, M.
HIV MEDICINE, 2018, 19 : S16 - S16
[44] Randomized, Double-blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 144 Results
Clumeck, Nathan
Molina, Jean-Michel
Henry, Keith
Gathe, Joseph
Rockstroh, Juergen K.
DeJesus, Edwin
Wei, Xuelian
White, Kirsten
Fordyce, Marshall W.
Rhee, Martin S.
Szwarcberg, Javier
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 65 (03) : E121 - E124
[45] SAFETY AND EFFICACY OF ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE IN TREATMENT-NAIVE JAPANESE PATIENTS WITH HIV-1 INFECTION
Yajima, K.
Yagura, H.
Yukawa, S.
Hirota, K.
Ikuma, M.
Kasai, D.
Watanabe, D.
Nishida, Y.
Uehira, T.
Shirasaka, T.
SEXUALLY TRANSMITTED INFECTIONS, 2015, 91 : A237 - A237
[46] Efficacy and safety of switching from boosted protease inhibitor plus emtricitabine/tenofovir disoproxil fumarate regimens to the single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults through 24 weeks: EMERALD study
Molina, J-M
Gallant, J.
Orkin, C.
Negredo, E.
Bhatti, L.
Gathe, J.
Van Landuyt, E.
Lathouwers, E.
Hufkens, V.
Vanveggel, S.
Opsomer, M.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2017, 20 : 28 - 28
[47] Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen in HIV-1 infection: a guide to its use in the EU
Deeks E.D.
Drugs & Therapy Perspectives, 2015, 31 (8) : 251 - 258
[48] Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI
Pozniak, Anton
Flamm, Jason
Antinori, Andrea
Bloch, Mark
Ward, Douglas
Berenguer, Juan
Cote, Pierre
Andreatta, Kristen
Garner, William
Szwarcberg, Javier
Nguyen-Cleary, Thai
McColl, Damian J.
Piontkowsky, David
HIV CLINICAL TRIALS, 2017, 18 (04): : 141 - 148
[49] Tenofovir/Emtricitabine plus Lopinavir/Ritonavir or Elvitegravir/cobicistat as a Single Tablet Regimen (STR) for PEP: A Randomized Clinical Trial
Inciarte, Alexy
Leal, Lorna
Leon, Agathe
Gonzalez, Eva
Torres, Berta
Lucero, Constanza
Mallolas, Josep
Laguno, Monserrat
Rojas, Jhon
Gatell, Josep
Garcia, Felipe
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2016, 32 : 389 - 389
[50] Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV
Xia, Huan
Huang, Xiao-Jie
Hu, Yue
Gao, Li-Ying
Wu, Yue
Wu, Hao
Yan, Zhong-Fang
Ma, Ping
CHINESE MEDICAL JOURNAL, 2021, 134 (23) : 2850 - 2856

← 1 2 3 4 5 →